GKA4 can exhibit potent anti-inflammatory and antioxidant effects against cisplatin-associated AKI, mediated by inhibiting the TLR-4/NF-κB/MAPK, HO-1/Nrf2, AMPK/SIRT1/NF-κB and PI3K/AKT axes (Figure 11). This evidence concerns the gene AKT1 and acute kidney injury.